InMode deepens declines amid lower expectations and Hagens Berman class action 📉

19:13 9 āđ€āļĄāļĐāļēāļĒāļ™ 2024

Israeli-based medical aesthetic equipment and technology company InMode (INMD.US) loses 9% in pre-market after series of class actions from Hagens Berman, Levi Korsinsky and The Gross Law as well as lower than expected revenues expectations. Not only 'higher for longer' central banks policy but also, Israeli-Gaza war and tensions with Iran negatively impact stock valuation. Previously, company informed that expects rebound in demand, as rates will be lowered but as for now is still unclear will Fed change its policy in summer of 2024.

Company will report full Q1 report on 2 May. As for now, Inmode expects full year 2024 revenues between $485 mln -$495 mln, below avg analysts' estimate of $498.8 mln. Also, Q1 guidance came in lower than expected. Inmode expects $80 mln - $80.1 mln vs average estimate of $102.2 mln. What's more, the aesthetics industry remains significantly affected by the macro environment challenges. On the other hand, company has almost 0 debt and still high both gross and net margins. However, it cyclical business has very strong headwinds as we can see in the stock chart.

āđ€āļĢāļīāđˆāļĄāđ€āļ—āļĢāļ”āļ—āļąāļ™āļ—āļĩāļ§āļąāļ™āļ™āļĩāđ‰ āļŦāļĢāļ·āļ­ āļĨāļ­āļ‡āđƒāļŠāđ‰āļšāļąāļāļŠāļĩāļ—āļ”āļĨāļ­āļ‡āđāļšāļšāđ„āļĢāđ‰āļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡

āđ€āļ›āļīāļ”āļšāļąāļāļŠāļĩ āļĨāļ­āļ‡āļšāļąāļāļŠāļĩāđ€āļ”āđ‚āļĄāđˆ āļ”āļēāļ§āļ™āđŒāđ‚āļŦāļĨāļ”āđāļ­āļ›āļĄāļ·āļ­āļ–āļ·āļ­ āļ”āļēāļ§āļ™āđŒāđ‚āļŦāļĨāļ”āđāļ­āļ›āļĄāļ·āļ­āļ–āļ·āļ­

Inmode (D1)

Shares are traded below SMA50 / SMA200, and today Wall Street session suggests opening at $17, which is historically the lowest level since company listing. The most important, technical resistance zone is now set at $20 and $22 per share.

Source: xStation5

āļŦāļļāđ‰āļ™:
āļāļĨāļąāļšāđ„āļ›

āļ‚āđˆāļēāļ§āđƒāļ™āļ•āļĨāļēāļ”āļāļēāļĢāđ€āļ‡āļīāļ™

02.08.2025
13:30

āļ”āļ­āļĨāļĨāļēāļĢāđŒāļ”āļīāđˆāļ‡ - āļˆāđ‰āļēāļ‡āļ‡āļēāļ™āļŠāļŦāļĢāļąāļāļŊ āļ—āļĢāļļāļ”

āļ•āļąāļ§āđ€āļĨāļ‚āļˆāđ‰āļēāļ‡āļ‡āļēāļ™āļ­āđˆāļ­āļ™āđāļ­āļāļĢāļ°āļ—āļšāđāļ™āļ§āļ„āļīāļ”āđ€āļĻāļĢāļĐāļāļāļīāļˆāļŠāļŦāļĢāļąāļāļŊ āļ—āļĩāđˆāļĒāļąāļ‡āđāļāļĢāđˆāļ‡ āđ‚āļ”āļĒ Kathleen Brooks, āļœāļđāđ‰āļ­āļģāļ™āļ§āļĒāļāļēāļĢāļāđˆāļēāļĒāļ§āļīāļˆāļąāļĒāļ‚āļ­āļ‡ XTB āļĢāļēāļĒāļ‡āļēāļ™āļāļēāļĢāļˆāđ‰āļēāļ‡āļ‡āļēāļ™āđ€āļ”āļ·āļ­āļ™āļāļĢāļāļŽāļēāļ„āļĄāļ­āđˆāļ­āļ™āđāļ­āļāļ§āđˆāļēāļ—āļĩāđˆāļ„āļēāļ”āđ„āļ§āđ‰...

01.08.2025
17:04

📉EURUSD āļ—āļ”āļŠāļ­āļšāļĢāļ°āļ”āļąāļš 1.14 āļāđˆāļ­āļ™āļ•āļąāļ§āđ€āļĨāļ‚ NFP āļŠāļŦāļĢāļąāļāļŊ

āļĢāļēāļĒāļ‡āļēāļ™ NFP: āļ•āļąāļ§āļŠāļĩāđ‰āļ§āļąāļ”āļŠāļģāļ„āļąāļāļ‚āļ­āļ‡āđ€āļĻāļĢāļĐāļāļāļīāļˆāļŠāļŦāļĢāļąāļāļŊ āļāđˆāļ­āļ™āļāļēāļĢāļ•āļąāļ”āļŠāļīāļ™āđƒāļˆāļ‚āļ­āļ‡ Fed āļĢāļēāļĒāļ‡āļēāļ™āļāļēāļĢāļˆāđ‰āļēāļ‡āļ‡āļēāļ™āļ™āļ­āļāļ āļēāļ„āđ€āļāļĐāļ•āļĢ (NFP) āļ–āļ·āļ­āđ€āļ›āđ‡āļ™āļŦāļ™āļķāđˆāļ‡āđƒāļ™āļ•āļąāļ§āđ€āļĨāļ‚āđ€āļĻāļĢāļĐāļāļāļīāļˆāļ—āļĩāđˆāļŠāļģāļ„āļąāļāļ—āļĩāđˆāļŠāļļāļ”āļ‚āļ­āļ‡āļŠāļŦāļĢāļąāļāļŊ...

16:21

āļ‚āđˆāļēāļ§āđ€āļ”āđˆāļ™: āđ€āļ‡āļīāļ™āđ€āļŸāđ‰āļ­āļĒāļđāđ‚āļĢāđ‚āļ‹āļ™āļ—āļĢāļ‡āļ•āļąāļ§āļ—āļĩāđˆ 2.0% – āļĒāļđāđ‚āļĢāļĒāļąāļ‡āļ­āđˆāļ­āļ™āļ„āđˆāļē

āđ€āļ‡āļīāļ™āđ€āļŸāđ‰āļ­āļĒāļđāđ‚āļĢāđ‚āļ‹āļ™āđ€āļ”āļ·āļ­āļ™āļāļĢāļāļŽāļēāļ„āļĄāļŠāļđāļ‡āļāļ§āđˆāļēāļ„āļēāļ”āđ€āļĨāđ‡āļāļ™āđ‰āļ­āļĒ – EUR/USD āļĒāļąāļ‡āļ„āļ‡āļ­āđˆāļ­āļ™āļ„āđˆāļē āđ€āļ‡āļīāļ™āđ€āļŸāđ‰āļ­āļ—āļąāđˆāļ§āđ„āļ› (Headline CPI): 2.0% YoY (āļ„āļēāļ”āļāļēāļĢāļ“āđŒ: 1.9%, āļ„āļĢāļąāđ‰āļ‡āļāđˆāļ­āļ™:...

āđ€āļ‚āđ‰āļēāļŠāļđāđˆāļ•āļĨāļēāļ”āļžāļĢāđ‰āļ­āļĄāļĨāļđāļāļ„āđ‰āļēāļ‚āļ­āļ‡ XTB Group āļāļ§āđˆāļē 1 600 000 āļĢāļēāļĒ

āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ—āļĩāđˆāđ€āļĢāļēāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡ āđ€āļĻāļĐāļŦāļļāđ‰āļ™ (Fractional Shares) āđ€āļ›āđ‡āļ™āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļĩāđˆāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļˆāļēāļ XTB āđāļŠāļ”āļ‡āļ–āļķāļ‡āļāļēāļĢāđ€āļ›āđ‡āļ™āđ€āļˆāđ‰āļēāļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļšāļēāļ‡āļŠāđˆāļ§āļ™āļŦāļĢāļ·āļ­ ETF āđ€āļĻāļĐāļŦāļļāđ‰āļ™āđ„āļĄāđˆāđƒāļŠāđˆāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ­āļīāļŠāļĢāļ° āļŠāļīāļ—āļ˜āļīāļ‚āļ­āļ‡āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ­āļēāļˆāļ–āļđāļāļˆāļģāļāļąāļ”
āļ„āļ§āļēāļĄāļŠāļđāļāđ€āļŠāļĩāļĒāļŠāļēāļĄāļēāļĢāļ–āđ€āļāļīāļ™āļāļ§āđˆāļēāđ€āļ‡āļīāļ™āļ—āļĩāđˆāļāļēāļ